Stockscreener 앱 받기
6.74
8.30%
-0.61
시간 외 거래:
6.74
전일 마감가:
$7.35
열려 있는:
$7.33
하루 거래량:
527.76K
Relative Volume:
0.59
시가총액:
$278.14M
수익:
$134.48M
순이익/손실:
$-38.94M
주가수익비율:
-7.0694
EPS:
-0.9534
순현금흐름:
$-19.34M
1주 성능:
-11.78%
1개월 성능:
-19.76%
6개월 성능:
-28.37%
1년 성능:
-72.88%
1일 변동 폭
$6.72
$7.53
1주일 범위
$6.72
$7.79
52주 변동 폭
$6.32
$27.13
Rxsight Inc Stock (RXST) Company Profile
명칭
Rxsight Inc
전화
949-521-7822
주소
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
6.74 | 303.31M | 134.48M | -38.94M | -19.34M | -0.9534 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | William Blair | Mkt Perform |
| 2025-07-15 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-07-09 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-09 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 개시 | Piper Sandler | Neutral |
| 2025-04-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-04-04 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2025-04-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-10-29 | 개시 | Jefferies | Buy |
| 2024-08-20 | 재확인 | Needham | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-05-07 | 재확인 | BTIG Research | Buy |
| 2023-12-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 개시 | Stifel | Buy |
| 2023-12-04 | 개시 | Morgan Stanley | Overweight |
| 2023-04-13 | 개시 | Oppenheimer | Outperform |
| 2022-12-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 개시 | Needham | Buy |
모두보기
Rxsight Inc 주식(RXST)의 최신 뉴스
RxSight (NASDAQ: RXST) details CFO sign-on bonus and corrects option vesting - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - ACCESS Newswire
Breakout Watch: What is RxSight Incs revenue forecast2026 Opening Moves & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Intraday: What is RxSight Incs revenue forecast2026 Biggest Moves & Entry Point Strategy Guides - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Stockholders to Connect - ACCESS Newswire
RXST Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Tech Rally: Is CNTY affected by consumer sentiment2026 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Reduce" by Analysts - MarketBeat
US Stocks Recap: What are the risks of holding RF Acquisition Corp IIPortfolio Performance Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Meridiem Capital Partners LP Buys New Position in RxSight, Inc. $RXST - MarketBeat
RxSight Inc Stock (ISIN: US78419L1008) Faces Analyst Pressure After Q4 Revenue Drop - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and RxSight (RXST) - The Globe and Mail
(RXST) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stifel cuts RxSight stock price target to $9 on revenue guidance - Investing.com South Africa
Stifel Lowers Price Target for RxSight (RXST) Following Recent A - GuruFocus
Stifel Nicolaus Has Lowered Expectations for RxSight (NASDAQ:RXST) Stock Price - MarketBeat
RxSight Inc. (RXST) PT Lowered to $9 at Stifel After Prudent Guidance - StreetInsider
RxSight Earnings Call: Strong Core, Cautious Outlook - TipRanks
RxSight downgraded at UBS after Q1 miss and guidance cut - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX) - The Globe and Mail
Wells Fargo Upgrades RxSight (RXST) - MSN
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Change - Yahoo Finance
RxSight announces executive leadership reorganization and new appointments - MSN
Midday Stock Roundup: Staar Falls 3.8% After Q4 Miss - Orange County Business Journal
Forecast Cut: Will RxSight Inc stock go up in YEARJuly 2025 Outlook & High Return Stock Watch Alerts - baoquankhu1.vn
RxSight (RXST) Q4 2025 Earnings Call Transcript - AOL.com
RxSight (RXST) CCO gains 6,261 shares, withholds 2,580 for taxes - Stock Titan
2026-03-03 | RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:RXST | Press Release - Stockhouse
RXST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
RxSight (RXST) CFO exercises 20,441 RSUs and withholds 8,068 shares for taxes - Stock Titan
Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-03-01 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
Artisan Partners Limited Partnership Cuts Position in RxSight, Inc. $RXST - MarketBeat
RXST Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
RxSight, Inc. (RXST) Investor Outlook: Exploring a 28% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
RxSight, Inc. (NASDAQ:RXST) Q4 2025 Earnings Call Transcript - Insider Monkey
RXSTRxsight, Inc. Latest Stock News & Market Updates - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), BioLife Solutions (BLFS) and RxSight (RXST) - The Globe and Mail
RxSight Reports Fourth Quarter and Fiscal Year Financial Results - VisionMonday.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Shareholders to Connect - ACCESS Newswire
Responsive Playbooks and the RXST Inflection - Stock Traders Daily
Needham reiterates Buy on RxSight stock, keeps $13 target By Investing.com - Investing.com Australia
RxSight (RXST) Loss Deepens In Q4 Results Reinforcing Bearish Profitability Narratives - simplywall.st
What 5 Analyst Ratings Have To Say About RxSight - Benzinga
UBS Increases Price Target for RXST to $9.00 While Maintaining N - GuruFocus
RxSight (NASDAQ:RXST) Given New $9.00 Price Target at UBS Group - MarketBeat
RXST: Piper Sandler Lowers Price Target to $10.00, Maintains Neu - GuruFocus
RxSight (NASDAQ:RXST) Price Target Lowered to $10.00 at Piper Sandler - MarketBeat
Rxsight Inc (RXST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):